PAION AG operates as a pharmaceutical company, which engages in the development of drugs to be used in out-patient and hospital-based sedation, anesthesia, and critical care services. The company is headquartered in Aachen, Nordrhein-Westfalen and currently employs 64 full-time employees. The company went IPO on 2005-02-11. The firm's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The firm operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Follow-Up Questions
Paion AG 'in CEO'su kimdir?
Mr. Gregor Siebert 2022 'den beri şirketle birlikte olan Paion AG 'in Chairman of the Management Board 'ıdır.
PAIOF hissesinin fiyat performansı nasıl?
PAIOF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Paion AG için ana iş temaları veya sektörler nelerdir?
Paion AG Biotechnology endüstrisine ait ve sektör Health Care 'dir
Paion AG 'in piyasa değerlemesi nedir?
Paion AG 'in mevcut piyasa değerlemesi $0 'dir
Paion AG al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 7 analist Paion AG için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 5 al, 1 tut, 0 sat ve 3 güçlü sat içermektedir
